ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma (039)

Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer characterized molecularly by oncogenic mutations and amplifications that can increase replication stress. A previous phase II study demonstrated the clinical activity of the oral small-molecule Wee1 kinase inhibitor adavosertib in USC (Liu et al. J Clin Oncol 2021;39:1531–9). This phase IIb single-arm, multicenter, global study (ADAGIO; NCT04590248) evaluated the efficacy and safety of adavosertib in patients with recurrent/persistent USC who had previously received platinum-based chemotherapy.